Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Colorectal and Ovarian Cancer Patients With Liver Metastases 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Abituzumab × Clear all
NCT00958477 2017-08-02

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled 44 charts
Genitourinary

Prostatic Neoplasms

NCT00848510 2015-12-14

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
41 enrolled 18 charts
GastrointestinalGynecologic

Colorectal and Ovarian Cancer Patients With Liver Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡